At 72 weeks, tirzepatide vs semaglutide produced 20.2% mean weight loss versus 13.7% in SURMOUNT-5, the first randomized head-to-head trial between them (NEJM, May 2025)
In addition to dopaminergic drugs, non-dopaminergic medications also play a significant role in the treatment of PD
With clinical trials documenting an average weight loss of 15 to 20 percent of body weight when combined with lifestyle adjustments, semaglutide emerges as an unrivaled choice among weight loss medications
Antioxid Redox Signal 13:17131748 He A, Dean JM, Lodhi IJ (2021a) Peroxisomes as cellular adaptors to metabolic and environmental stress
By optimizing cellular energy pathways, it can lead to increased vitality and stamina
doi: 10.1007/s12325-020-01464-1 61 JohansenPHuntBIyerNNDang-TanTPollockRF